for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunomedics, Inc.

IMMU.O

Latest Trade

18.40USD

Change

0.00(0.00%)

Volume

1,454,675

Today's Range

18.24

 - 

19.01

52 Week Range

11.55

 - 

21.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Immunomedics Reports Third Quarter Loss Per Share Of $0.49

Oct 30 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS REPORTS THIRD QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.49.Q3 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.COMPANY HAD NO REVENUES FOR QUARTER.

Immunomedics Q2 Loss Per Share $0.40

Aug 7 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS REPORTS SECOND QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.40.Q2 EARNINGS PER SHARE ESTIMATE $-0.30 -- REFINITIV IBES DATA.RESUBMISSION OF BIOLOGICS LICENSE APPLICATION ON TRACK FOR EARLY Q4 2019.HAD NO REVENUES FOR QUARTER AND SIX MONTHS ENDED JUNE 30, 2019.

Immunomedics Reports Q1 Results

May 9 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS REPORTS FIRST QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.46.Q1 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, COMPANY HAD $442.7 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES.

Immunomedics Inc - Michael Pehl Has Stepped Down From Role Of President, CEO And Member Of Board

Feb 25 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS REPORTS RESULTS FOR PERIOD ENDED DECEMBER 31, 2018, STRENGTHENS BOARD AND ANNOUNCES SENIOR LEADERSHIP CHANGES.IMMUNOMEDICS INC - CHARLES BAUM, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF MIRATI THERAPEUTICS, INC. HAS JOINED BOARD.IMMUNOMEDICS INC - MICHAEL PEHL HAS STEPPED DOWN FROM ROLE OF PRESIDENT, CEO AND MEMBER OF BOARD.IMMUNOMEDICS INC - INTERIM CHIEF FINANCIAL OFFICER, USAMA MALIK, HAS BEEN APPOINTED CFO.

Immunomedics Says FDA Will Be Conducting Re-Inspection Of Co's Morris Plains Facility

Feb 7 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS INC - ON FEBRUARY 4, 2019, IMMUNOMEDICS RECEIVED A WRITTEN COMMUNICATION FROM FDA.IMMUNOMEDICS INC - FDA NOTIFIED COMPANY THAT FDA WILL BE CONDUCTING A RE-INSPECTION OF COMPANY'S MORRIS PLAINS, NEW JERSEY MANUFACTURING FACILITY.IMMUNOMEDICS INC - FINALIZING ITS PLANS WITH RESPECT TO MATTERS RAISED IN COMPLETE RESPONSE LETTER RECEIVED FROM FDA ON JANUARY 17, 2019.IMMUNOMEDICS INC - COMPANY EXPECTS TO REQUEST A MEETING WITH FDA IN NEAR TERM.

Immunomedics Receives Complete Response Letter From FDA For Sacituzumab Govitecan Biologics License Application

Jan 17 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR SACITUZUMAB GOVITECAN BIOLOGICS LICENSE APPLICATION.IMMUNOMEDICS -CO GOING TO REQUEST MEETING WITH FDA AS SOON AS POSSIBLE TO GAIN FULL UNDERSTANDING OF AGENCY'S REQUIREMENTS AND TIMELINES FOR APPROVAL.WILL WORK CLOSELY WITH FDA WITH GOAL OF BRINGING MEDICINE TO PATIENTS AS SOON AS POSSIBLE.

Johnson Matthey Partners With Immunomedics To Develop Cancer Treatment

Jan 9 (Reuters) - Johnson Matthey::JOHNSON MATTHEY PLC - CO PARTNERS WITH IMMUNOMEDICS TO DEVELOP CANCER TREATMENT.JOHNSON MATTHEY PLC - MANUFACTURING PARTNERSHIP IS FOR LARGE-SCALE PRODUCTION OF THE DRUG-LINKER USED IN IMMUNOMEDICS’ LEAD ANTIBODY-DRUG CONJUGATE.

Immunomedics Inc Says On December 20, Co Entered Into A Letter Agreement BSP Pharmaceuticals S.P.A.

Dec 28 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS INC - ON DECEMBER 20, CO ENTERED INTO A LETTER AGREEMENT BSP PHARMACEUTICALS S.P.A..IMMUNOMEDICS INC - TO NEGOTIATE AGREEMENT FOR COMMERCIAL SUPPLY BY BSP TO COMPANY OF COMPANY'S ANTIBODY-DRUG CONJUGATE SACITUZUMAB GOVITECAN.IMMUNOMEDICS INC - COMPANY WILL BE RESPONSIBLE TO ORDER A MINIMUM AMOUNT OF BULK DRUG SUBSTANCE AND DRUG PRODUCT FOR PRODUCTION IN 2019 AND 2020.IMMUNOMEDICS - FOR THE MINIMUM ORDERS IN 2019 AND 2020, AN AGGREGATE OF EUR 23 MILLION IS DUE IN 2019, EUR 23.7 MILLION IS DUE IN 2020 AS CONSIDERATION.

Immunomedics Q1 Loss Per Share $0.34

Nov 7 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2019 RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.34.Q1 REVENUE $700,000.Q1 EARNINGS PER SHARE VIEW $-0.28 -- THOMSON REUTERS I/B/E/S.Q1 REVENUE VIEW $1.9 MILLION -- THOMSON REUTERS I/B/E/S.

Immunomedics Enters Exchange Agreements With Outstanding 4.75 pct Convertible Note Holders

Oct 3 (Reuters) - Immunomedics Inc <IMMU.O>::IMMUNOMEDICS-ON OCT 2, ENTERED INTO EXCHANGE AGREEMENTS WITH LIMITED NUMBER OF HOLDERS OF OUTSTANDING 4.75% CONVERTIBLE SENIOR NOTES DUE 2020.IMMUNOMEDICS INC - COMPANY ANTICIPATES THE EXCHANGES WILL BE COMPLETED ON OR ABOUT OCTOBER 5, 2018 - SEC FILING.IMMUNOMEDICS - UPON COMPLETION OF EXCHANGES, AGGREGATE AMOUNT OF CONVERTIBLE NOTES IS EXPECTED TO BE REDUCED TO ABOUT $7.1 MILLION.IMMUNOMEDICS INC - UPON COMPLETION OF EXCHANGES, AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE NOTES IS EXPECTED TO BE REDUCED TO ABOUT $7.1 MILLION.IMMUNOMEDICS-AGREED TO EXCHANGE ABOUT $12.9 MILLION CONVERTIBLE NOTES HELD BY NOTEHOLDERS FOR ABOUT 2.57 MILLION NEWLY ISSUED SHARES OF CO'S COMMON STOCK.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up